论文部分内容阅读
本文报告了临床或病理确诊的98例原发性肝癌及269例非原发性肝癌疾患的血清AFP放射免疫测定结果。阳性率(>25ng/ml)分别为76.53％及28.25％原发性肝癌组AFP含量多呈高水平>400ng/ml升高,动态检测呈进行性升高或持续高水平。非原发性肝癌组则以低水平(25—200ng/ml)升高为主,超过肝癌阈值的(占7.81％)则多为一时性或在1—2个月内即恢复正常。AFP浓度的这种变化规律有助于两者的鉴别。并分析了原发性肝癌的AFP假阴性及非肝癌疾患的AFP呈高水平升高的可能因素,提出在临床应用中应注意综合分析及加强动态观察。
This article reports the results of serum AFP radioimmunoassay for 98 cases of primary liver cancer and 269 cases of non-primary liver cancer diagnosed clinically or pathologically. The positive rate (>25 ng/ml) was 76.53% and the AFP content in the 28.25% primary hepatocellular carcinoma group had a high level of >400 ng/ml, and the dynamic test showed a progressive increase or sustained high level. The non-primary liver cancer group was mainly elevated at a low level (25-200 ng/ml), and those that exceeded the liver cancer threshold (7.81%) were mostly temporary or normal within 1-2 months. This change in AFP concentration helps to identify the two. The probable factors of high-level increase of AFP false negative and non-hepatocellular carcinoma of primary liver cancer were analyzed. It is proposed that comprehensive analysis and enhanced dynamic observation should be paid attention to in clinical application.